Allogene Therapeutics Inc. [NASDAQ: ALLO] gained 15.74% on the last trading session, reaching $7.94 price per share at the time. The company report on January 24, 2023 that Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple Myeloma.
Allogene Therapeutics Inc. represents 143.66 million in outstanding shares, while the company has a total market value of $1.11 billion with the latest information. ALLO stock price has been found in the range of $7.09 to $8.10.
If compared to the average trading volume of 1.89M shares, ALLO reached a trading volume of 3860657 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Allogene Therapeutics Inc. [ALLO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALLO shares is $22.53 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALLO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Allogene Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 24, 2023. The new note on the price target was released on January 06, 2023, representing the official price target for Allogene Therapeutics Inc. stock. Previously, the target price had yet another drop from $24 to $9, while BofA Securities kept a Underperform rating on ALLO stock.
The Average True Range (ATR) for Allogene Therapeutics Inc. is set at 0.58, with the Price to Sales ratio for ALLO stock in the period of the last 12 months amounting to 5567.53. The Price to Book ratio for the last quarter was 1.54, with the Price to Cash per share for the same quarter was set at 3.94.
Trading performance analysis for ALLO stock
Allogene Therapeutics Inc. [ALLO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.24. With this latest performance, ALLO shares gained by 27.04% in over the last four-week period, additionally sinking by -41.70% over the last 6 months – not to mention a drop of -30.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALLO stock in for the last two-week period is set at 62.30, with the RSI for the last a single of trading hit 72.19, and the three-weeks RSI is set at 55.23 for Allogene Therapeutics Inc. [ALLO]. The present Moving Average for the last 50 days of trading for this stock 7.89, while it was recorded at 6.84 for the last single week of trading, and 10.31 for the last 200 days.
Allogene Therapeutics Inc. [ALLO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Allogene Therapeutics Inc. [ALLO] shares currently have an operating margin of -664.58 and a Gross Margin at +66.06. Allogene Therapeutics Inc.’s Net Margin is presently recorded at -667.74.
Return on Equity for this stock declined to -25.75, with Return on Assets sitting at -22.68.
Allogene Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.60 and a Current Ratio set at 11.60.
Allogene Therapeutics Inc. [ALLO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Allogene Therapeutics Inc. go to 1.00%.
An analysis of insider ownership at Allogene Therapeutics Inc. [ALLO]
There are presently around $836 million, or 76.20% of ALLO stock, in the hands of institutional investors. The top three institutional holders of ALLO stocks are: TPG GP A, LLC with ownership of 18,716,306, which is approximately 0% of the company’s market cap and around 0.60% of the total institutional ownership; BLACKROCK INC., holding 8,212,580 shares of the stock with an approximate value of $65.21 million in ALLO stocks shares; and VANGUARD GROUP INC, currently with $56.88 million in ALLO stock with ownership of nearly -14.788% of the company’s market capitalization.
Positions in Allogene Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 110 institutional holders increased their position in Allogene Therapeutics Inc. [NASDAQ:ALLO] by around 12,217,418 shares. Additionally, 61 investors decreased positions by around 6,788,180 shares, while 32 investors held positions by with 86,296,313 shares. The mentioned changes placed institutional holdings at 105,301,911 shares, according to the latest SEC report filing. ALLO stock had 44 new institutional investments in for a total of 2,572,697 shares, while 12 institutional investors sold positions of 234,646 shares during the same period.